Projects per year
Abstract
Introduction: Carnosine is a naturally occurring dipeptide abundant in the skeletal and cardiac muscle and brain, which has been shown to improve glucose metabolism and cardiovascular risk. This study showed that carnosine supplementation had positive changes on plasma lipidome. Here, this study aimed to establish the relationship of muscle carnosine and serum carnosinase-1 with cardiometabolic risk factors and the lipidome. Methods and Results: This study profiles >450 lipid species in 65 overweight/obese nondiabetic individuals. Intensive metabolic testing is conducted using direct gold-standard measures of adiposity, insulin sensitivity and secretion, as well as measurement of serum inflammatory cytokines and adipokines. Muscle carnosine is negatively associated with 2-h glucose concentrations, whereas serum carnosinase-1 levels are negatively associated with insulin sensitivity and positively with IL-18. O-PLS and machine learning analyses reveal a strong association of muscle carnosine with ether lipids, particularly arachidonic acid-containing plasmalogens. Carnosinase-1 levels are positively associated with total phosphatidylethanolamines, but negatively with lysoalkylphosphatidylcholines, trihexosylceramides, and gangliosides. In particular, alkylphosphatidylethanolamine species containing arachidonic acid are positively associated with carnosinase-1. Conclusion: These associations reinforce the role of muscle carnosine and serum carnosinase-1 in the interplay among low-grade chronic inflammation, glucose homeostasis, and insulin sensitivity.
Original language | English |
---|---|
Article number | 2100164 |
Number of pages | 9 |
Journal | Molecular Nutrition and Food Research |
Volume | 65 |
Issue number | 20 |
DOIs | |
Publication status | Published - Oct 2021 |
Keywords
- carnosine
- iron
- lipidomics
- muscle
- obesity
-
Plasma Lipidomic Signatures for Risk Prediction and Prevention of Gestational Diabetes
1/01/19 → 31/12/25
Project: Research
-
Can vitamin D prevent diabetes by improving insulin sensitivity and secretion in overweight humans?
de Courten, B. (Primary Chief Investigator (PCI)), De Courten, M. (Chief Investigator (CI)), Scragg, R. (Chief Investigator (CI)) & Walker, K. (Chief Investigator (CI))
National Health and Medical Research Council (NHMRC) (Australia)
1/01/14 → 31/12/17
Project: Research